On May 15, 2019 Seattle Genetics, Inc. (Nasdaq:SGEN) reported data from six of its proprietary programs will be presented at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2019 Annual Meeting taking place May 31 to June 4, 2019 in Chicago (Press release, Seattle Genetics, MAY 15, 2019, View Source [SID1234536358]). More than 10 sessions at the meeting will feature Seattle Genetics’ approved or investigational therapies, including an oral presentation of the results from the enfortumab vedotin pivotal trial. The abstracts published in advance of the ASCO (Free ASCO Whitepaper) meeting were made available today on the ASCO (Free ASCO Whitepaper) website at www.asco.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Data to be presented on our approved or investigational targeted medicines support our efforts toward becoming a multi-product oncology company," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. "Importantly, the oral presentation of the results from the EV-201 pivotal trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer is our first solid tumor late-stage development program. We are also presenting updated analyses from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS (brentuximab vedotin) that is approved for several types of lymphomas."
Details of the oral presentation:
Abstract Title: EV-201: Results of Enfortumab Vedotin Monotherapy for Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Platinum and Immune Checkpoint Inhibitors
Abstract: #LBA4505
Presenter: Daniel P. Petrylak, M.D., Yale School of Medicine
Date and Time: Monday, June 3, 9:24-9:36 a.m. CDT
Location: Arie Crown Theater
Details of select company- or investigator-sponsored presentations are as follows:
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma: Three-year Update of the ECHELON-1 Study (Abstract #7532)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #286
Response to A+CHP by CD30 Expression in the ECHELON-2 Trial (Abstract #7538)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #292
Response to Brentuximab Vedotin by CD30 Expression: Results from Five Trials in PTCL, CTCL, and B-cell Lymphomas (Abstract #7543)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #297
Tucatinib, Palbociclib, and Letrozole in HR+/HER2+ Metastatic Breast Cancer: Report of Phase IB Safety Cohort (Abstract #1029)
Date and Time: Sunday, June 2, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #110
Performance of FACT-GOG-Ntx to Assess Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Pediatric Hodgkin lymphoma (HL) Patients (Abstract #10064)
Date and Time: Saturday, June 1, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #446
Details of company-sponsored trials in progress presentations are as follows:
SGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors (Abstract #TPS3160)
Date and Time: Saturday, June 1, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #145a
Phase 2 Trial of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer (innovaTV 208) (Abstract #TPS5602)
Date and Time: Saturday, June 1, 1:15 p.m.-4:15 p.m. CDT
Location: Hall A, Poster Board #421a
SGNLVA-002: Single-Arm, Open Label Phase IB/II Study of Ladiratuzumab Vedotin (LV) in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (Abstract #TPS1110)
Date and Time: Sunday, June 2, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #186a
SGNBCMA-001: A Phase 1 Study of SEA-BCMA, a Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma (Abstract #TPS8054)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m. CDT
Location: Hall A, Poster Board #379a
EV-103: Enfortumab Vedotin Plus Pembrolizumab and/or Chemotherapy for Locally Advanced or Metastatic Urothelial Cancer (Abstract #TPS4593)
Date and Time: Monday, June 3, 1:15 p.m.-4:15 p.m. CDT
Location: Hall A, Poster Board #415b